Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$9.84 USD
+0.18 (1.86%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.82 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OLMA 9.84 +0.18(1.86%)
Will OLMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OLMA
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?
Other News for OLMA
Buy Rating Affirmed for Olema Pharmaceuticals Amid Promising Clinical Trial Results for Breast Cancer Therapy
Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination
Notable Thursday Option Activity: OLMA, TRC, CRWD
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
OPEN, BCRX and AWIN among pre-market gainers